Antimicrobial management of complicated intra-abdominal infections caused by resistant bacteria

European Infectious Disease

Volumn 6, Issue 1, 2012, Pages 22-27

  Eckmann, Christian ^a   Shekarriz, Hodjat ^b  

^a Klinikum Peine   (France)

^b Department of Gener Visceral and Thoracic Surgery   (Germany)

Author keywords

Carbapenem resistant bacteria; Complicated intra abdominal infections; Extended spectrum beta lactamase producing Enterobacteriaceae; Post operative peritonitis; Resistant bacteria; Tertiary peritonitis; Vancomycin resistant enterococci

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FOSFOMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CRITICALLY ILL PATIENT; DRUG SAFETY; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; MEDICAL INFORMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; PERITONITIS; PHARMACODYNAMICS; PSEUDOMONAS; SURGICAL APPROACH;

EID: 84865131168     PISSN: 17551137     EISSN: 17551145     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Kumar A, Roberts D, Wood KE, et al., Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, Crit Care Med, 2006;34:1589-96.
2. Kumar A, Ellis P, Arabi Y, et al., Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock, Chest, 2009;136:1237-48.
3. Engel C, Brunkhorst FM, Bone HG, et al., Epidemiology of sepsis in Germany: results from a national prospective multicenter study, Intensive Care Med, 2007;33:606-18.
4. Wong PF, Gilliam AD, Kumar S, et al., Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults, Cochrane Database Syst Rev, 2005;(2):CD004539.
5. Edelsberg J, Berger A, Schell S, et al., Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections, Surg Infect (Larchmt), 2008;9:335-47.
6. Barie P, The cost of failure, Surg Infect (Larchmt), 2008;9:313-5.
7. Davey PG, Marwick C, Appropriate versus inappropriate antimicrobial therapy, Clin Microbiol Infect, 2008;14(Suppl. 3):S15-S21.
8. Solomkin JS, Mazuski JE, Bradley JS, et al., Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America, Clin Infect Dis, 2010;50:133-64.
9. Weigelt JA, Empiric treatment options in the management of complicated intra-abdominal infections, Cleve Clin J Med, 2007;74(Suppl. 4):S29-37.
10. Eckmann C, Dryden M, Montravers P, et al., Antimicrobial treatment of 'complicated' intra-abdominal infections and the new IDSA guidelines - a commentary and an alternative European approach according to clinical definitions, Eur J Med Res, 2011;16:115-26.
11. Augustin P, Kermarrec N, Muller-Serieys C, Montravers P, Risk factors for multi-drug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis, Crit Care, 2010;14:R20.
12. Bader F, Schroeder M, Kujath P, et al., Diffuse postoperative peritonitis: value of diagnostic parameters and impact of early indication for relaparotomy, Eur J Med Res, 2009;14:1-6.
13. Govindarajulu S, Hawley CM, McDonald SP, et al., Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases, Perit Dial Int, 2010;30:311-9.
14. Dupont H, The empiric treatment of nosocomial intra-abdominal infections, Int J Infect Dis, 2007;11(Suppl. 1):S1-6.
15. Harbarth S, Uckay I, Are there any patients with peritonitis who require empiric therapy for enterococcus?, Eur J Microbiol Infect Dis, 2004;23:73-7.
16. Chromik AM, Meiser A, Hölling J, et al., Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit, J Gastrointest Surg, 2009;13:1358-67.
17. Krepel CJ, Gohr CM, Edmiston CE, Condon RE, Surgical sepsis: constancy of antibiotic susceptibility of causative organisms, Surgery, 1995;117:505-9.
18. De Waele JJ, Hoste EA, Blot SI, Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death, Surg Infect (Larchmt), 2008;9:171-7.
19. Roehrborn A, Thomas L, Potreck O, et al., The microbiology of postoperative peritonitis, Clin Infect Dis, 2001;33:1513-9.
20. Boucher HW, Talbot GH, Bradley JS, et al., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis, 2009;48:1-12.
21. Hawser S, Hoban D, Bouchillon S, et al., Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008, Eur J Clin Microbiol Infect Dis, 2011;30(2):173-9.
22. Eckmann C, Heizmann WR, Leitner E, et al., Prospective, non-interventional multicentre trial of tigecycline in the treatment of severely ill patients with complicated infections - new insights into clinical results and treatment practice, Chemotherapy, 2011;57:275-84.
23. Oxford Centre of Evidence-based Medicine: levels of evidence, March 2009. Available at: www.cebm.net/index.aspx?o=1025 (accessed 15 January 2011).
24. Ebell MH, Siwek J, Weiss BD, et al., Strength of recommendation taxonomy a patient-centered approach to grading evidence in the medical literature, J Am Board Fam Pract, 2004;17:59-67.
25. Eckmann C, Isenmann R, Kujath P, et al., In: Bodmann KF, Grabein B, et al., Recommendations of the Paul-Ehrlich-society for chemotherapy for the empirical antimicrobial treatment of severe infections of adults: Intra-abdominal infections, Chemother J, 2010;19:217-22.
26. Takatsuki M, Eguchi S, Yamanouchi K, et al., The outcomes of methicillin-resistant Staphylococcus aureus infection after living donor liver transplantation in a Japanese center, J Hepatobiliary Pancreat Sci, 2010;17(6):839-43.
27. Babinchak T, Ellis-Grosse E, Dartois N, et al., The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections, Clin Infect Dis, 2005;41(Suppl. 5):S354-67.
28. Swoboda S, Ober M, Hainer C, et al., Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug evaluation in a surgical intensive care unit, J Antimicrob Chemother, 2008;61:729-33.
29. Bassetti M, Nicolini L, Repetto E, et al., Tigecycline use in serious nosocomial infections: a drug use evaluation, BMC Infect Dis, 2010;10:287.
30. Itani KMF, Dryden MS, Bhattacharyya H, et al., Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus, Am J Surg, 2010;199:804-16.
31. Arbeit RD, Maki D, Tally FP, et al., The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections, Clin Infect Dis, 2004;38:1673-81.
32. Birmingham MC, Rayner CR, Meagher AM, et al., Linezolid in the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program, Clin Infect Dis, 2003;36:159-68.
33. Salzer W, Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them, Perit Dial Int, 2005;25:313-9.
34. Cercenado E, Torroba L, Cantón R, et al., Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis, J Clin Microbiol, 2010;48:456-9.
35. Nickols RL, Muzik AC, Enterococcal infections in surgical patients: the mystery continues, Clin Infect Dis, 1992;15:72-6.
36. Piroth L, Pechinot A, Minello A, et al., Bacterial epidemiology and antimicrobial resistance in ascites fluid: a 2-year retrospective study, Scand J Infect Dis, 2009;41:847-51.
37. Aslangul E, Ruimy R, Chau F, et al., Relationship between the level of acquired resistance to gentamicin and synergism with amoxicillin in Enterococcus faecalis, Antimicrob Agents Chemother, 2005;49:4144-8.
38. Lefort A, Arthur M, Garry L, et al., Bactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo, Antimicrob Agents Chemother, 2000;44:2077-80.
39. Halle E, Padberg J, Rosseau S, et al., Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany, Infection, 2004;32:182-3.
40. Livermore DM, Beta-lactamases in laboratory and clinical resistance, Clin Microbiol Rev, 1995;8:557-84.
41. Lehner S, Grabein B, Pfaller P, Kopp R, [Relevance of ESBL-producing pathogens for clinical surgery: diagnostics, therapy and prevention], Chirurg, 2009;80:527-36.
42. Masterton RG, Galloway A, French G, et al., Guidelines for the management of hospital-acquired pneumonia in the UK, J Antimicrob Chemother, 2008;62:5-34.
43. Giske CG, Monnet DL, Cars O, Carmeli Y, Clinical and economic impact of common multidrug-resistant Gram-negative bacilli, Antimicrob Agents Chemother, 2008;52:813-21.
44. DiNubile MJ, Friedland I, Chan CY, et al., Bowel colonization with resistant Gram-negative bacilli after antimicrobial therapy of intra-abdominal infections, Eur J Microbiol Infect Dis, 2005;24:443-9.
45. Sotto A, Lefrant JY, Fabbro-Peray P, et al., Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis, J Antimicrob Chemother, 2002;50:569-72.
46. Driscoll JA, Brody SL, Kollef MH, The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections, Drugs, 2007;67:351-68.
47. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al., Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation, Transpl Infect Dis, 2012;14(2):198-205.
48. Hirsch EB, Tam VH, Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection, J Antimicrob Chemother, 2010;65:1119-25.
49. Di Carlo P, Pantuso G, Cusimano A, et al., Two cases of monomicrobial intraabdominal abscesses due to KPC - 3 Klebsiella pneumoniae ST258 clone, BMC Gastroenterol, 2011;11:103.
50. US Food and Drug Administration, FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at: www.fda.gov/Drugs/DrugSafety/ucm224370.htm (accessed 15 January 2011).
51. Dryden M, Complicated skin and soft tissue infection, J Antimicrob Chemother, 2010;65(Suppl. 3):iii35-44.
52. Wilcox MH, The tide of antimicrobial resistance and selection, Int J Antimicrob Agents, 2009;34(Suppl. 3):S6-10.
53. Nathwani D, New antibiotics for the management of complicated skin and soft tissue infections: are they any better?, Int J Antimicrob Agents, 2009;34(Suppl. 1):S24-9.
54. Eckmann C, Dryden M, Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin, Eur J Med Res, 2010;15:554-63.
55. Takesue Y, Nakajima K, Ichiki K, et al., Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant gram-negative bacteria, J Hosp Infect, 2010;75:28-32.
56. Caínzos M, Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections--are they applicable today?, Clin Microbiol Infect, 2008;14(Suppl. 6):9-18.
57. Bouadma L, Luyt CE, Tubach F, et al., Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial, Lancet, 2010;375(9713):463-74.